We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RJX is an IV formulation being developed for treatment of inflammatory disorders, including COVID-19 patients with viral sepsis, multi-system inflammation, cytokine release syndrome, shock, ARDS and multi-organ failure.